Evaluating the predictive value of Senescence Marker Protein 30 and Peroxiredoxin1 suspected with pulmonary embolism

Aim: Pulmonary thromboembolism (PTE) cannot be easy diagnosed because of nonspecific symptoms and signs of patients applying to emergency departments. There is no highly specific noninvasive diagnostic biomarker to be used in PTE diagnosis algorithms. In this study, the predictive value of senescence marker protein 30 (SMP30) and peroxiredoxin1 (PRDX1) in the suspicion of pulmonary embolism has been evaluated . Materials-Methods: Sixty-one pulmonary embolism suspected patients who got spiral computerized tomographic pulmonary angiography were included in the study. Patients who were diagnosed as PTE were in PTE group (n=26) and patient who were not diagnosed as PTE were accepted as control (=35) group. From both groups serum samples were taken to measure serum PRDX1 and SMP30 levels. Results: Median (min-max) PRDX1 levels were 10,21(0,58-22,23) ng/mL in the patients with PTE and 4,7(0,01-17,65) ng/mL in the control group. Median (min-max) SMP30 levels were 20,4(0,4-128,8) ng/mL in the patients with PTE and 32,3(0,5-120) ng/mL in the control group. PRDX1 levels were significantly higher in the patients with PE (p = 0.001), but, for SMP30 levels, there were no statistical significance between these two groups (p=0.37). Conclusions: In this study PRDX1 values in the patients with PTE were found to be significantly higher, whereas there were no statistical significance between these two groups for SMP30 levels. This suggests that measurement of serum PRDX1 may be a distinctive marker for the diagnosis of PTE, but, for SMP30 this can not be suggested. Further studies involving larger case series and also clinical studies are needed to collaborate these findings. Key Words: Pulmonary Embolism, Biomarker, PRDX1, SMP30